EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts

Tsung-Chieh Yao iD, Sheng-Mao Chang iD, Yi-Fen Tsai iD, Shuo-Ju Chiang iD, Hui-Ju Tsai iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70311 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Tsung-Chieh Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Hemorrhage, Anticoagulants, Adrenal Cortex Hormones, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The choice of oral anticoagulants and oral corticosteroid (OCS) burst cotherapy may influence the risk of major bleeding; however, this risk remains poorly characterized. We aimed to quantify the comparative safety of non–vitamin K oral anticoagulants (NOACs) versus warfarin on major bleeding while receiving OCS burst cotherapy among patients with atrial fibrillation. A nationwide population‐based cohort study was conducted using the National Health Insurance Research Database. We examined associations between NOACs (edoxaban, apixaban, dabigartran, or rivaroxaban) or warfarin with OCS burst cotherapy and major bleeding. We measured the risk by estimating incidence, incidence risk ratios (IRRs), and adjusted hazard ratios (AHRs) after adjusting for baseline differences using overlap weighting. In this study, among 239,693 patients receiving oral anticoagulants, 50,390 (21%) received at least one OCS burst, defined as OCS use for less than 30 days, were included. A lower risk of major bleeding related to OCS burst cotherapy with NOACs versus warfarin was noted (AHR = 0.57 [95% CI = 0.52–0.61]). The greatest incidence was observed in patients with warfarin and OCS burst cotherapy (67.30 per 1000 person‐years). The incidence for patients prescribing OCS burst cotherapy with edoxaban (30.36 per 1000 person‐years; IRR = 0.45 [95% CI = 0.38–0.53]), apixaban (34.93 per 1000 person‐years; IRR = 0.52 [95% CI = 0.45–0.60]), dabigatran (42.47 per 1000 person‐years; IRR = 0.63 [95% CI = 0.56–0.72]), and rivaroxaban (46.99 per 1000 person‐years; IRR = 0.70 [95% CI = 0.63–0.77]), separately, was lower than that with warfarin. The results reveal that the incidence of major bleeding was lowest for edoxaban and highest for warfarin, with notable differences in incidence rates across NOACs among patients receiving oral anticoagulants and OCS burst cotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageAnticoagulantsAdrenal Cortex HormonesAtrial FibrillationHumansMaleFemaleAgedIncidenceMiddle AgedAdministration, OralWarfarinAged, 80 and overDrug Therapy, CombinationRisk FactorsRisk AssessmentRetrospective StudiesPyridonesRivaroxabanPyrazolesPyridinesThiazoles

Stichwörter der Autor:innen

atrial fibrillationmajor bleedingnon–vitamin K anticoagulantoral corticosteroidwarfarin

Substanzen

AnticoagulantsAdrenal Cortex HormonesWarfarinapixabanPyridonesRivaroxabanedoxabanPyrazolesPyridinesThiazoles

Autor:innen und Institutionen

  • Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Department of Statistics, National Taipei University, Taipei, Taiwan.
  • Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Taipei City Hospital, Taipei, Taiwan.
  • Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Tsung-Chieh Yao, Sheng-Mao Chang, Yi-Fen Tsai, Shuo-Ju Chiang, Hui-Ju Tsai

Zitieren

APA

Yao, T. C., Chang, S. M., Tsai, Y. F., Chiang, S. J., & Tsai, H. J. (2025). Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts. Clinical and Translational Science. https://doi.org/10.1111/cts.70311

Vancouver

Yao TC, Chang SM, Tsai YF, Chiang SJ, Tsai HJ. Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts. Clinical and Translational Science. 2025. doi:10.1111/cts.70311

BibTeX
@article{Yao2025,
  author = {Yao, Tsung-Chieh and Chang, Sheng-Mao and Tsai, Yi-Fen and Chiang, Shuo-Ju and Tsai, Hui-Ju},
  title = {Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70311}
}
Kostenlos starten →